Evidence map›Paper›PMID 36831099›Full record

ArticleBiomedicines2023

Scandium-44 Radiolabeled Peptide and Peptidomimetic Conjugates Targeting Neuropilin-1 Co-Receptor as Potential Tools for Cancer Diagnosis and Anti-Angiogenic Therapy.

Katarzyna Masłowska, Patrycja Redkiewicz, Paweł Krzysztof Halik, Ewa Witkowska, Dagmara Tymecka, Rafał Walczak, Jarosław Choiński, Aleksandra Misicka, Ewa Gniazdowska

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Scandium-44: Diagnostic Feasibility in Tumor-Related Angiogenesis.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Katarzyna MasłowskaCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, 03-195 Warsaw, Poland.
Patrycja RedkiewiczDepartment of Neuropeptides, Mossakowski Medical Research Institute Polish Academy of Sciences, 02-106 Warsaw, Poland.ORCID 0000-0001-8654-580X
Paweł Krzysztof HalikCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, 03-195 Warsaw, Poland.ORCID 0000-0003-0657-3793
Ewa WitkowskaFaculty of Chemistry, University of Warsaw, 02-093 Warsaw, Poland.
Dagmara TymeckaFaculty of Chemistry, University of Warsaw, 02-093 Warsaw, Poland.ORCID 0000-0002-8909-4087
Rafał WalczakCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, 03-195 Warsaw, Poland.
Jarosław ChoińskiHeavy Ion Laboratory, University of Warsaw, 02-093 Warsaw, Poland.ORCID 0000-0003-3195-3050
Aleksandra MisickaDepartment of Neuropeptides, Mossakowski Medical Research Institute Polish Academy of Sciences, 02-106 Warsaw, Poland.ORCID 0000-0001-7446-2396
Ewa GniazdowskaCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, 03-195 Warsaw, Poland.ORCID 0000-0001-7446-1115
Instytut Chemii i Techniki Jądrowej · PLUniversity of Warsaw · PLMossakowski Medical Research Institute, Polish Academy of Sciences · PL

Funding

National Science Centre (Poland) 2019/33/B/NZ7/02818
6 · The paper itself

Abstract

Pathological angiogenesis, resulting from an imbalance between anti- and pro-angiogenic factors, plays a pivotal role in tumor growth, development and metastasis. The inhibition of the angiogenesis process by the VEGF/VEGFR-2/NRP-1 pathway raises interest in the search for such interaction inhibitors for the purpose of the early diagnosis and treatment of angiogenesis-dependent diseases. In this work we designed and tested peptide-based radiocompounds that selectively bind to the neuropilin-1 co-receptor and prevent the formation of the pro-angiogenic VEGF-A

Indexed as

A7R peptideangiogenesisangiogenic factorsanti-angiogenic therapyneuropilin-1peptidomimeticsretro-inverso isomer DR7Atheranostic 43,44,47Sc-radiopharmaceuticalsVEGF-A165/NRP-1 complex inhibitor

Identifiers

PMID36831099
PMCPMC9953004
OpenAlexW4320918406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.